LifeMD (LFMD) Stock Forecast & Price Target

LifeMD Inc has demonstrated robust growth in its Telehealth segment, achieving a 14% year-over-year increase in its active subscriber base, totaling 310,818 by the end of the third quarter of 2025. The company reported total revenue of $60.2 million, reflecting a 12.7% year-over-year growth, with Telehealth revenue specifically rising by 17.4% to $47.3 million, highlighting the increasing demand for telehealth services. Additionally, recent product offerings, including competitive pricing for Novo's GLP-1 medications, and a strong emphasis on building a comprehensive telehealth infrastructure, position LifeMD favorably for continued growth in the evolving healthcare landscape.

LifeMD Inc.'s recent revenue report revealed figures of $60.2 million, which marked a 13% year-over-year increase but fell short of analyst expectations, leading to concerns about slower growth in its telehealth segment. The company faces significant risks, including lower projected telehealth revenue growth, difficulties in patient acquisition and retention, and increased competition from lower-cost alternatives, which are anticipated to hinder profitability. Additionally, the revised full-year revenue guidance for 2025 highlights the challenges faced by the company, with telehealth revenue now expected to be between $192 million and $193 million, reflecting the pressures from competitors in the market.